practice. Treatment with the CTLA -4 -like CD80/86 ligand abatacept, which has precisely the opposite effect of ipilimumab, has been recommended for several AI diseases [12] [13] [14] .
Similar to what is observed with animal models, when compared to ipilimumab, the newer anti -PD -1/PD -L1 inhibitors seem to offer greater safety 15 , which could be explained by the less specific effect of CTLA -4 inhibition on T cell activation 16 . The combined use of CTLA -4 and PD -1 blockade is associated with a higher risk of irAEs but may result in relevant clinical synergism and survival benefit 17, 18 .
Diverse mechanisms have been proposed to understand the physiopathology of irAEs: 1) cross -reactivity may occur when T -cells increase their activity against tumoral antigens that might resemble auto--antigens expressed on healthy tissues 19 ; 2) PD -1/PD -L1 appear to play a role in modulating humoral immunity, helping to maintain self--tolerance 20 ; ICPI might disrupt an immunologic equilibrium, increasing auto -antibodies that were previously not pathologic; 3) elevated levels of inflammatory cytokines may contribute to the lesions seen with ICPI, such as podocyte foot process effacement seen with podocytopathies 21, 22 ; 4) complement -mediated inflammation due to direct binding of an ICPI to its receptor expressed on normal tissue can contribute to aggravate the lesions on healthy tissues 6 .
RENAL DAMAGE
The kidney is one of the multiple organs affected by ICPI. First trials estimated an overall incidence of acute kidney injury (AKI) of 2.2%, with increased frequency when the combination ipilimumab/nivolumab was used (4.9%) 2 . However, with the widespread use of ICPI, AKI has been estimated to be as high as 29% 23 . As the population on immunotherapy grows and diversifies, a more extensive range of toxicities has been unfolding. Different grading systems limit the reports on AKI since the Common Terminology Criteria for Adverse Events (CTCAE) used to classify nephrotoxicity in cancer patients differs from the highly validated KDIGO criteria. The former does not consider lower grade kidney injury as defined by the KDIGO criteria (Table 2 ). Another aspect that prevents an adequate report on immunotherapy nephrotoxicity is the fact that urinary samples are frequently omitted at first evaluations, which makes interpretations of altered urinary tests difficult after starting therapy, considering that kidney complications are common in cancer patients 24, 25 . Hence, the true incidence of kidney involvement seen with ICPI is probably underestimated.
Acute tubulointerstitial nephritis
The most common kidney manifestation seen with ICPI is AKI due to acute tubulointerstitial nephritis (ATIN), which seems to be present most of the time, even when other renal complications develop, such as vasculitis or glomerular injury 22, 26 . However, ATIN, in this context, differs from the typical drug -induced reaction. To start with, there is a highly variable temporal pattern: it has been described up to 22 months 27 after initiation of ICPI, and there have been case reports of reactions more than 8 weeks after taking the last dose of immunotherapy 2 , which contrasts with the 7 -10 days usually observed after the beginning of the offending drug associated with classical ATIN 28 .
Similarly, there isn't a clear causality between drug exposure and AKI. On the one hand, Gallan et al. describe a case in which AKI relapsed one month after stopping corticosteroids (CCT), even without resuming the offending ICPI 26 . On the other hand, some patients were repeatedly exposed to the same drug, without any further event, as demonstrated by Cortazar et al. 2 It has been hypothesized that uninhibited T cells may lead to drug--induced hypersensitivity that, when a known immunogenic molecule is involved (ex. nonsteroidal anti -inflammatory drugs or proton pump inhibitors), could cause ATIN. The case presented by Koda et al. is a good illustration, with a positive drug -induced lymphocyte stimulation test for lansoprazole alerting for the importance of recognizing medications known to cause ATIN 29 .
This assumption, though, differs from what is observed in animal models, where the absence of immune checkpoints suffices to cause ATIN 11 . The latter is also evident in patients with no known exposure to conventional nephrotoxic therapies that have also developed ATIN 27, 30 .
Clinically, patients typically present with AKI that might sometimes be oliguric, pyuria, hematuria, and proteinuria that is usually bland 2, 27, 31 , such as seen in other cases of classic ATIN 28 . Eosinophilia is a rare finding. Other irAEs often develop before or with AKI 2,27 .
Renal biopsies show tubulointerstitial infiltrates and edema, with a predominance of CD3+ mononuclear T cells. Granulomas and eosinophils may be present, although they are neither sensitive nor specific for ICPI--associated ATIN 29, 30, [32] [33] [34] . Cassol et al. have identified a particular immunohistochemistry staining pattern for PD -L1 in inflammatory and tubular epithelial cells that seems to be only found in ICPI -induced ATIN 27 .
Other renal findings
Glomerular lesions are less commonly found, although there has been growing literature on the subject, with reports on lupus 22 , where they describe their findings, such as AA amyloidosis, membranous nephropathy (negative for anti -phospholipase -A2 receptor), IgA and pauci -immune GN, c3 glomerulopathy and FSGS. It is crucial to notice, however, that previous urinalyses were not available for most of the cases (11 of 16), making it hard to exclude paraneoplastic syndromes.
Renal vasculitis has also been linked to ICPI in several reports 22, 26 . It is yet unknown why the same drug may be related to so many distinct renal reactions.
Electrolyte disturbances
Different electrolyte disturbances have been associated with immunotherapy. The most common is hyponatremia, which is usually secondary to hypophysitis and hypopituitarism 23, 43 . Electrolyte disorders may relate to several other irAEs (eg., diarrhea from colitis) or concomitant clinical features of cancer itself (eg., anorexia, nausea, and vomiting), making it difficult to assess a real causal effect of ICPI. According to Manohar et al., hypocalcemia is the only that has been significantly associated with PD -1 inhibitors, although the authors couldn't find a reasonable explanation 44 .
TREATMENT STRATEGY AND KIDNEY RECOVERY
The ESMO Clinical Practice Guidelines on the management of toxicities from immunotherapy 45 propose the following approach, depending on the CTCAE staging system: The American Society of Clinical Oncology Clinical Practice Guideline for the Management of IrAEs in patients treated with ICPI 46 has similar recommendations but adds: if creatinine elevations persist or worsen > 3 -5 days (G3) or >2 -3 days (G4), consider additional immunosuppression (e.g., mycophenolate). Although the prognosis is usually favorable, with an excellent response to CCT and generally with complete recovery of the renal function, some patients show a corticoresistant or corticodependent behavior that requires other immunosuppressors, such as mycophenolate 2, 22, 37 . The same drug has previously been used for the treatment of classic ATIN from different etiologies, with effective results 47 . Other therapies have been proposed, based on positive results observed with other organ toxicities, as is the case of infliximab, usually employed in the management of colitis. Mamlouke et al. report its successful use in patients with ATIN or IgA nephropathy attributed to ICPI 22 . Depending on the renal toxicity, other immunosuppressors might additionally be necessary, as is the case of rituximab for the treatment of vasculitis 22 . However, Gallan et al. describe 3 patients with vasculitis that was successfully treated with CCT only 26 .
Up to this moment, CCT seem to be the mainstay of therapy for irAEs. Other immunosuppressors should be considered on a case -by--case basis. So far, no prospective trials have defined the best treatment approach, and current recommendations are based solely on expert consensus.
One of the most important questions raised when facing an irAEs is whether ICPI may be safely resumed. A few studies have addressed the safety of restarting therapy, with inconsistent results. A retrospective study with 38 patients treated with anti -PD1 or anti -PDL1 who had irAEs that required either a delay in treatment or CCTs (or both) and were later exposed to ICPI again showed that 50% had no further irAEs, 24% had a recurrence of the first event, and 26% had a different irAE 48 . Cortazar et al. describe 2 patients who were rechallenged with ICPI, neither of whom had other renal irAEs 2 . Nakatany et al. describe another case where nivolumab was restarted (while on 5mg methylprednisolone) with no further occurrence 30 . Other authors, however, had less favorable outcomes. Glutsch et al. report a patient with whom, despite altering ICPI classes, the nephrotic syndrome reappeared 35 . Kitchlu et al. describe another patient whose nephrotic syndrome recurred after re -exposure to ipilimumab 40 . It is still unclear why only a few patients will have a reoccurrence and what might help to predict and prevent it.
The ESMO Clinical Practice Guidelines consider the possibility to restart ICPI, as described in 5) above. The decision to stop life -saving therapies is not straight -forward and should be a matter of multidisciplinary discussion. Patients with higher AKI stages (≥ stage 2) should be referred to Nephrology consultation to evaluate the cause of renal dysfunction. A renal biopsy might differentiate an acute tubular necrosis (ATN) from a real irAE requiring ICPI suspension, CCT, or other immunosuppressors, while at the same time avoiding unnecessary toxicity or delays in treatment. The evidence presented by Izzedine et al. shows that ATN might account for a large part of kidney dysfunction (5 of 12 patients presented with ATN alone) 42 .
The safety of retreatment also depends on the severity of the irAE. A life -threatening toxicity should be regarded as an absolute contra--indication to resume immunotherapy 6 .
Another pertinent issue frequently raised is whether CCT or other immunosuppressors negatively impact the treatment of cancer. Current evidence shows that patients treated for irAEs did not have worse outcomes [49] [50] [51] . Some papers further suggest that irAEs correlate with a better cancer response 51 
. PATIENTS AT INCREASED RISK FOR ADVERSE EVENTS
Patients with previous AI diseases are at increased risk for irAEs. Data on these patients are scarce since they have been excluded from most clinical trials. In the few retrospective studies that involved patients with a history of AI disease [52] [53] [54] , 27 -38% had a flare. In the survey conducted by Menzies et al., only 4% (2 of 20) had to stop treatment for this reason 52 . Among the population with AI diseases in the study led by Johnson et al., all flares were successfully managed with CCT 53 . Danlos et al. also demonstrate that treatment with anti--PD1 was maintained in most patients with previous AI dysfunctions, despite irAEs, and cancer treatment was just as effective 54 . The relatively rare reports of a high -grade flare from an existing AI disease suggests that patients with a life -threatening cancer might be considered for immunotherapy after careful multidisciplinary discussion, pending close clinical and analytical vigilance 6 . When it comes to transplanted patients with life -threatening cancer, the transplanted organ should be taken into consideration. Kidney failure might be treated with dialysis, whereas other organs failure might be more challenging to handle. Still, it should be decided on a case -by -case approach.
Patients with renal insufficiency were also excluded from most clinical trials. A prospective study with atezolizumab involved patients with a glomerular filtration rate between 30 -60ml/min, who had a comparable response to therapy 58 . ICPI are not cleared by the kidneys, so they should be just as effective and safe for patients with chronic kidney disease. The findings of Kanz et al. corroborate this. The authors identified 17 patients on ICPI with renal dysfunction, including 3 on hemodialysis, that didn't have worse disease responses or more irAEs 59 . Herz et al. report another 4 patients with kidney failure, one of them with a kidney graft, that had stable renal function, and no irAE (or rejection) 60 . CONCLUSION ICPI represent a massive advance in the treatment of cancer, and their revolutionary results are being explored in a growing field of diseases and patients. Evidence shows that renal toxicities are probably much more common than initially reported. Up to this moment, there are no validated biomarkers for the prediction of ICPI toxicity, thus its management relies on an early diagnosis and high suspicion that should lead to a prompt and aggressive use of CCT or other immunosuppressors. Renal biopsy may play a crucial role. The multiple potential organ toxicities demand a multidisciplinary approach, and the nephrologists should be ready to take part in the diagnosis and treatment strategy.
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